Clinical Trial Update: Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study [Phase 3]

View source ↗

Summary

This Phase 3 extension study reports the safety findings for buprenorphine transdermal systems in adults with chronic nonmalignant pain over 28 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmalignant Pain

Drugs mentioned

• BUPRENORPHINE TRANSDERMAL SYSTEM (buprenorphine)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Chronic Nonmalignant Pain | Phase 3 | Status: COMPLETED | Results posted: 2010-09-23